Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Medication Adherence | 98 | 2023 | 2063 | 14.880 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 43 | 2023 | 3255 | 4.370 |
Why?
|
Cardiovascular Agents | 20 | 2019 | 850 | 4.340 |
Why?
|
Insurance, Pharmaceutical Services | 15 | 2019 | 336 | 3.470 |
Why?
|
Drugs, Generic | 21 | 2016 | 421 | 2.950 |
Why?
|
Antihypertensive Agents | 21 | 2023 | 2047 | 2.950 |
Why?
|
Drug Prescriptions | 27 | 2019 | 1636 | 2.950 |
Why?
|
Hypertension | 25 | 2023 | 8480 | 2.870 |
Why?
|
Hypoglycemic Agents | 20 | 2021 | 2877 | 2.860 |
Why?
|
Prescription Drugs | 17 | 2023 | 593 | 2.730 |
Why?
|
Chronic Disease | 20 | 2021 | 9139 | 2.550 |
Why?
|
Drug Costs | 24 | 2023 | 1105 | 2.460 |
Why?
|
Community Pharmacy Services | 6 | 2019 | 46 | 2.460 |
Why?
|
Pharmaceutical Services | 7 | 2018 | 140 | 2.210 |
Why?
|
Cost Sharing | 14 | 2020 | 407 | 2.060 |
Why?
|
Myocardial Infarction | 34 | 2022 | 11708 | 2.030 |
Why?
|
Health Expenditures | 16 | 2023 | 2348 | 1.970 |
Why?
|
Patient Compliance | 15 | 2019 | 2683 | 1.960 |
Why?
|
Insurance Claim Review | 15 | 2020 | 719 | 1.780 |
Why?
|
Drug Utilization | 15 | 2018 | 1183 | 1.680 |
Why?
|
Reminder Systems | 5 | 2018 | 371 | 1.570 |
Why?
|
Warfarin | 11 | 2018 | 1497 | 1.520 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 13 | 2020 | 1516 | 1.500 |
Why?
|
Coronary Artery Bypass | 9 | 2015 | 2288 | 1.440 |
Why?
|
Adrenergic beta-Antagonists | 12 | 2020 | 1240 | 1.400 |
Why?
|
Pharmacists | 5 | 2019 | 248 | 1.370 |
Why?
|
Drug Labeling | 7 | 2016 | 233 | 1.370 |
Why?
|
United States | 106 | 2023 | 69859 | 1.360 |
Why?
|
Insurance Coverage | 12 | 2016 | 1900 | 1.350 |
Why?
|
Prescriptions | 4 | 2023 | 387 | 1.320 |
Why?
|
Pharmacies | 12 | 2021 | 150 | 1.300 |
Why?
|
Diabetes Mellitus | 17 | 2021 | 5752 | 1.300 |
Why?
|
Cardiovascular Diseases | 27 | 2023 | 15142 | 1.250 |
Why?
|
Anticoagulants | 15 | 2019 | 4599 | 1.210 |
Why?
|
Atrial Fibrillation | 16 | 2018 | 5033 | 1.210 |
Why?
|
Diabetes Mellitus, Type 2 | 14 | 2021 | 11729 | 1.210 |
Why?
|
Polypharmacy | 4 | 2021 | 294 | 1.170 |
Why?
|
Humans | 287 | 2024 | 743811 | 1.150 |
Why?
|
Ticlopidine | 9 | 2016 | 899 | 1.140 |
Why?
|
Hyperlipidemias | 7 | 2018 | 789 | 1.130 |
Why?
|
Platelet Aggregation Inhibitors | 15 | 2020 | 3070 | 1.100 |
Why?
|
Insurance, Health | 9 | 2017 | 2492 | 1.080 |
Why?
|
Metformin | 6 | 2023 | 837 | 1.030 |
Why?
|
Cost Savings | 7 | 2019 | 925 | 1.020 |
Why?
|
Health Benefit Plans, Employee | 3 | 2015 | 332 | 1.020 |
Why?
|
Female | 162 | 2024 | 380020 | 1.000 |
Why?
|
Middle Aged | 114 | 2023 | 213241 | 0.990 |
Why?
|
Medicare | 21 | 2020 | 6565 | 0.980 |
Why?
|
Male | 151 | 2024 | 349776 | 0.980 |
Why?
|
Medication Therapy Management | 5 | 2018 | 127 | 0.970 |
Why?
|
Cohort Studies | 54 | 2023 | 40545 | 0.960 |
Why?
|
Purinergic P2Y Receptor Antagonists | 7 | 2022 | 362 | 0.940 |
Why?
|
Aged | 103 | 2024 | 163178 | 0.920 |
Why?
|
Thiophenes | 5 | 2014 | 589 | 0.920 |
Why?
|
Cost-Benefit Analysis | 24 | 2020 | 5388 | 0.910 |
Why?
|
Blood Pressure | 8 | 2023 | 8551 | 0.910 |
Why?
|
Commerce | 5 | 2016 | 592 | 0.900 |
Why?
|
Physicians | 12 | 2022 | 4569 | 0.890 |
Why?
|
Secondary Prevention | 9 | 2020 | 1529 | 0.880 |
Why?
|
Drug Substitution | 3 | 2016 | 281 | 0.880 |
Why?
|
Patient-Centered Care | 5 | 2017 | 1438 | 0.870 |
Why?
|
Prescription Fees | 7 | 2014 | 146 | 0.840 |
Why?
|
Physical Therapy Modalities | 2 | 2023 | 549 | 0.840 |
Why?
|
Cost Control | 6 | 2017 | 624 | 0.830 |
Why?
|
Telemedicine | 4 | 2021 | 2874 | 0.810 |
Why?
|
Inappropriate Prescribing | 2 | 2021 | 202 | 0.800 |
Why?
|
Alopecia Areata | 1 | 2023 | 107 | 0.800 |
Why?
|
Insulin | 5 | 2020 | 6584 | 0.790 |
Why?
|
Telephone | 5 | 2022 | 617 | 0.760 |
Why?
|
Health Care Costs | 6 | 2020 | 3207 | 0.740 |
Why?
|
Electronic Health Records | 6 | 2021 | 4467 | 0.720 |
Why?
|
Angiotensin Receptor Antagonists | 5 | 2020 | 923 | 0.720 |
Why?
|
Uncompensated Care | 2 | 2009 | 34 | 0.690 |
Why?
|
Quality-Adjusted Life Years | 9 | 2019 | 1683 | 0.680 |
Why?
|
Reinforcement, Social | 1 | 2018 | 10 | 0.680 |
Why?
|
beta-Alanine | 3 | 2014 | 74 | 0.670 |
Why?
|
Adrenergic beta-1 Receptor Antagonists | 1 | 2018 | 30 | 0.660 |
Why?
|
Quality of Health Care | 10 | 2018 | 4370 | 0.660 |
Why?
|
Medical Assistance | 2 | 2009 | 104 | 0.660 |
Why?
|
Hypolipidemic Agents | 5 | 2018 | 606 | 0.650 |
Why?
|
Retrospective Studies | 46 | 2023 | 77410 | 0.650 |
Why?
|
Logistic Models | 17 | 2021 | 13404 | 0.640 |
Why?
|
Patient Education as Topic | 7 | 2016 | 2278 | 0.640 |
Why?
|
Postal Service | 1 | 2018 | 96 | 0.640 |
Why?
|
Healthcare Disparities | 6 | 2016 | 3155 | 0.640 |
Why?
|
Osteoporosis | 4 | 2017 | 1577 | 0.640 |
Why?
|
Metoprolol | 1 | 2018 | 93 | 0.630 |
Why?
|
Frail Elderly | 1 | 2023 | 693 | 0.630 |
Why?
|
Patient Participation | 2 | 2017 | 1457 | 0.620 |
Why?
|
Self Report | 7 | 2023 | 3550 | 0.620 |
Why?
|
Spinal Diseases | 1 | 2022 | 538 | 0.610 |
Why?
|
Pyridones | 4 | 2017 | 711 | 0.600 |
Why?
|
Financing, Organized | 2 | 2009 | 202 | 0.600 |
Why?
|
Myocardial Revascularization | 6 | 2016 | 841 | 0.600 |
Why?
|
Medicare Part D | 3 | 2015 | 328 | 0.600 |
Why?
|
Vaccination | 3 | 2023 | 3275 | 0.590 |
Why?
|
Glycemic Index | 1 | 2020 | 394 | 0.590 |
Why?
|
Financing, Personal | 5 | 2014 | 308 | 0.590 |
Why?
|
Analgesics, Opioid | 7 | 2023 | 3677 | 0.590 |
Why?
|
Health Insurance Portability and Accountability Act | 1 | 2017 | 99 | 0.590 |
Why?
|
Randomized Controlled Trials as Topic | 13 | 2021 | 9944 | 0.580 |
Why?
|
Insurance Carriers | 2 | 2021 | 157 | 0.570 |
Why?
|
Patient Preference | 3 | 2019 | 889 | 0.570 |
Why?
|
Conflict of Interest | 3 | 2011 | 544 | 0.570 |
Why?
|
Medicare Part C | 1 | 2021 | 296 | 0.570 |
Why?
|
Benzimidazoles | 4 | 2015 | 850 | 0.560 |
Why?
|
Pharmaceutical Preparations | 4 | 2016 | 1070 | 0.550 |
Why?
|
Fee-for-Service Plans | 2 | 2020 | 694 | 0.550 |
Why?
|
Morpholines | 3 | 2014 | 571 | 0.550 |
Why?
|
Coronary Disease | 7 | 2011 | 6078 | 0.530 |
Why?
|
Comparative Effectiveness Research | 4 | 2017 | 680 | 0.530 |
Why?
|
Complementary Therapies | 1 | 2020 | 485 | 0.530 |
Why?
|
Adult | 62 | 2023 | 213889 | 0.530 |
Why?
|
Pharmacy Service, Hospital | 1 | 2016 | 133 | 0.530 |
Why?
|
Drug Industry | 6 | 2012 | 746 | 0.520 |
Why?
|
Diabetes Complications | 2 | 2020 | 1360 | 0.520 |
Why?
|
New Jersey | 5 | 2020 | 290 | 0.520 |
Why?
|
Medical Informatics | 1 | 2022 | 745 | 0.520 |
Why?
|
Databases, Factual | 18 | 2018 | 7729 | 0.510 |
Why?
|
Aryl Hydrocarbon Hydroxylases | 2 | 2013 | 257 | 0.500 |
Why?
|
Immunization | 1 | 2019 | 1255 | 0.500 |
Why?
|
Administration, Oral | 9 | 2019 | 3912 | 0.500 |
Why?
|
Propensity Score | 11 | 2018 | 1781 | 0.500 |
Why?
|
Decision Support Systems, Clinical | 2 | 2018 | 1164 | 0.500 |
Why?
|
Medication Reconciliation | 1 | 2016 | 151 | 0.500 |
Why?
|
Drug Therapy, Combination | 14 | 2017 | 6487 | 0.490 |
Why?
|
Renal Dialysis | 3 | 2012 | 1783 | 0.490 |
Why?
|
Hospitalization | 9 | 2023 | 10259 | 0.490 |
Why?
|
Low Back Pain | 1 | 2023 | 956 | 0.490 |
Why?
|
Research Design | 8 | 2021 | 5983 | 0.480 |
Why?
|
Guideline Adherence | 6 | 2014 | 2265 | 0.480 |
Why?
|
Primary Health Care | 7 | 2023 | 4556 | 0.470 |
Why?
|
Guidelines as Topic | 2 | 2020 | 1404 | 0.470 |
Why?
|
Deductibles and Coinsurance | 4 | 2020 | 316 | 0.470 |
Why?
|
Diphosphonates | 2 | 2017 | 622 | 0.460 |
Why?
|
Health Services Needs and Demand | 3 | 2022 | 1411 | 0.460 |
Why?
|
Pharmacogenetics | 2 | 2014 | 674 | 0.460 |
Why?
|
Cost of Illness | 3 | 2015 | 1859 | 0.460 |
Why?
|
Imidazoles | 2 | 2017 | 1206 | 0.450 |
Why?
|
United States Food and Drug Administration | 11 | 2015 | 1582 | 0.450 |
Why?
|
Confidentiality | 1 | 2017 | 613 | 0.440 |
Why?
|
Pharyngitis | 1 | 2014 | 215 | 0.440 |
Why?
|
Models, Economic | 4 | 2019 | 712 | 0.430 |
Why?
|
Socioeconomic Factors | 12 | 2020 | 7784 | 0.430 |
Why?
|
Drug Recalls | 1 | 2012 | 17 | 0.430 |
Why?
|
Stockings, Compression | 1 | 2012 | 37 | 0.430 |
Why?
|
Quality Improvement | 3 | 2020 | 3750 | 0.420 |
Why?
|
Pain, Postoperative | 4 | 2017 | 1642 | 0.420 |
Why?
|
Treatment Outcome | 35 | 2023 | 63042 | 0.420 |
Why?
|
Aged, 80 and over | 30 | 2023 | 57744 | 0.420 |
Why?
|
Otitis Media | 1 | 2014 | 277 | 0.420 |
Why?
|
Evidence-Based Medicine | 9 | 2019 | 3608 | 0.420 |
Why?
|
Cephalosporins | 1 | 2013 | 203 | 0.410 |
Why?
|
Medical Records | 1 | 2017 | 1412 | 0.410 |
Why?
|
Pyrazoles | 4 | 2017 | 1970 | 0.410 |
Why?
|
Intention to Treat Analysis | 3 | 2018 | 426 | 0.410 |
Why?
|
Drug Approval | 2 | 2011 | 742 | 0.400 |
Why?
|
Postoperative Complications | 6 | 2018 | 15281 | 0.400 |
Why?
|
Patients | 3 | 2010 | 899 | 0.400 |
Why?
|
Renal Insufficiency | 2 | 2016 | 805 | 0.400 |
Why?
|
Markov Chains | 5 | 2015 | 968 | 0.400 |
Why?
|
Quality Assurance, Health Care | 3 | 2010 | 2211 | 0.400 |
Why?
|
Practice Guidelines as Topic | 9 | 2019 | 7270 | 0.400 |
Why?
|
Decision Making | 6 | 2022 | 3887 | 0.400 |
Why?
|
Coronary Artery Disease | 5 | 2013 | 6485 | 0.400 |
Why?
|
Blood Loss, Surgical | 1 | 2015 | 660 | 0.390 |
Why?
|
Kidney Failure, Chronic | 3 | 2012 | 2534 | 0.390 |
Why?
|
Life Change Events | 1 | 2016 | 938 | 0.390 |
Why?
|
Ambulatory Care Facilities | 2 | 2014 | 934 | 0.390 |
Why?
|
Blood Glucose | 4 | 2020 | 6259 | 0.390 |
Why?
|
Referral and Consultation | 5 | 2022 | 3530 | 0.380 |
Why?
|
Enterocolitis, Pseudomembranous | 1 | 2013 | 264 | 0.380 |
Why?
|
Costs and Cost Analysis | 3 | 2014 | 1680 | 0.380 |
Why?
|
Health Services Accessibility | 7 | 2015 | 5136 | 0.380 |
Why?
|
Cesarean Section | 2 | 2017 | 1365 | 0.380 |
Why?
|
Communication | 6 | 2022 | 3748 | 0.380 |
Why?
|
Renal Insufficiency, Chronic | 2 | 2018 | 2200 | 0.370 |
Why?
|
Disclosure | 3 | 2011 | 737 | 0.370 |
Why?
|
Health Behavior | 2 | 2022 | 2634 | 0.370 |
Why?
|
Heparin, Low-Molecular-Weight | 1 | 2012 | 339 | 0.370 |
Why?
|
Pharmacy | 2 | 2022 | 91 | 0.370 |
Why?
|
Data Collection | 4 | 2015 | 3339 | 0.360 |
Why?
|
Medication Errors | 3 | 2016 | 798 | 0.360 |
Why?
|
Legislation, Drug | 2 | 2014 | 206 | 0.360 |
Why?
|
Capital Financing | 1 | 2010 | 58 | 0.360 |
Why?
|
Matched-Pair Analysis | 3 | 2013 | 288 | 0.360 |
Why?
|
Piperazines | 4 | 2017 | 2487 | 0.360 |
Why?
|
Patient Discharge | 6 | 2018 | 3317 | 0.360 |
Why?
|
Medicaid | 7 | 2019 | 2736 | 0.360 |
Why?
|
Anticonvulsants | 3 | 2016 | 1910 | 0.360 |
Why?
|
Time Factors | 20 | 2020 | 40038 | 0.360 |
Why?
|
Risk Factors | 27 | 2023 | 72252 | 0.350 |
Why?
|
Technology | 2 | 2023 | 302 | 0.350 |
Why?
|
Patient Acceptance of Health Care | 3 | 2018 | 3020 | 0.350 |
Why?
|
Vancomycin | 1 | 2013 | 501 | 0.350 |
Why?
|
Specialization | 1 | 2014 | 775 | 0.350 |
Why?
|
Influenza, Human | 2 | 2018 | 1480 | 0.350 |
Why?
|
Medical Staff, Hospital | 2 | 2021 | 601 | 0.350 |
Why?
|
Pharmacy Administration | 1 | 2009 | 3 | 0.350 |
Why?
|
Voluntary Health Agencies | 1 | 2009 | 39 | 0.350 |
Why?
|
Pennsylvania | 8 | 2019 | 613 | 0.340 |
Why?
|
Encephalitozoon | 1 | 2009 | 5 | 0.340 |
Why?
|
Vascular Diseases | 2 | 2008 | 1161 | 0.340 |
Why?
|
Heart Failure | 6 | 2024 | 10896 | 0.340 |
Why?
|
Aromatase Inhibitors | 1 | 2013 | 487 | 0.340 |
Why?
|
Nonprescription Drugs | 2 | 2012 | 116 | 0.340 |
Why?
|
Internationality | 3 | 2014 | 1002 | 0.330 |
Why?
|
Fluorobenzenes | 1 | 2011 | 183 | 0.330 |
Why?
|
Family | 3 | 2018 | 3144 | 0.330 |
Why?
|
Bone Density Conservation Agents | 4 | 2015 | 768 | 0.330 |
Why?
|
Industry | 2 | 2010 | 366 | 0.330 |
Why?
|
Publications | 1 | 2011 | 195 | 0.330 |
Why?
|
Economic Competition | 2 | 2008 | 214 | 0.330 |
Why?
|
Age Factors | 11 | 2019 | 18355 | 0.320 |
Why?
|
Urinary Tract Infections | 1 | 2014 | 788 | 0.320 |
Why?
|
Quality Indicators, Health Care | 3 | 2020 | 1831 | 0.310 |
Why?
|
Food Supply | 1 | 2014 | 524 | 0.310 |
Why?
|
Antidepressive Agents | 2 | 2017 | 2837 | 0.310 |
Why?
|
Antibiotic Prophylaxis | 1 | 2013 | 638 | 0.310 |
Why?
|
Health Records, Personal | 1 | 2009 | 124 | 0.310 |
Why?
|
Young Adult | 21 | 2019 | 56392 | 0.310 |
Why?
|
Aspirin | 4 | 2013 | 3283 | 0.300 |
Why?
|
Drug and Narcotic Control | 2 | 2008 | 146 | 0.300 |
Why?
|
Renin-Angiotensin System | 1 | 2012 | 758 | 0.300 |
Why?
|
Blood Pressure Determination | 2 | 2022 | 633 | 0.300 |
Why?
|
Enterocytes | 1 | 2009 | 225 | 0.300 |
Why?
|
Health Status Disparities | 2 | 2016 | 1796 | 0.290 |
Why?
|
Odds Ratio | 10 | 2024 | 9848 | 0.290 |
Why?
|
Patient Care | 2 | 2020 | 638 | 0.290 |
Why?
|
Insurance, Health, Reimbursement | 1 | 2010 | 397 | 0.290 |
Why?
|
Hepatitis C, Chronic | 1 | 2015 | 1029 | 0.280 |
Why?
|
Genetic Testing | 3 | 2014 | 3439 | 0.280 |
Why?
|
Product Surveillance, Postmarketing | 3 | 2015 | 430 | 0.280 |
Why?
|
Income | 5 | 2020 | 1913 | 0.280 |
Why?
|
Prevalence | 6 | 2021 | 15211 | 0.280 |
Why?
|
Long-Term Care | 3 | 2020 | 606 | 0.280 |
Why?
|
American Heart Association | 2 | 2021 | 1057 | 0.280 |
Why?
|
Models, Statistical | 3 | 2017 | 5100 | 0.270 |
Why?
|
Antithrombins | 3 | 2018 | 304 | 0.270 |
Why?
|
Cardiac Tamponade | 1 | 2007 | 173 | 0.270 |
Why?
|
Follow-Up Studies | 13 | 2020 | 39001 | 0.270 |
Why?
|
Stroke | 11 | 2019 | 9975 | 0.270 |
Why?
|
Managed Care Programs | 1 | 2011 | 950 | 0.270 |
Why?
|
Drug Utilization Review | 5 | 2016 | 245 | 0.270 |
Why?
|
Immunosuppressive Agents | 1 | 2019 | 4152 | 0.270 |
Why?
|
Anti-Arrhythmia Agents | 2 | 2018 | 788 | 0.270 |
Why?
|
Intracranial Hemorrhages | 1 | 2011 | 855 | 0.260 |
Why?
|
Antiviral Agents | 2 | 2015 | 2984 | 0.260 |
Why?
|
Evidence-Based Practice | 3 | 2019 | 500 | 0.260 |
Why?
|
Health Personnel | 3 | 2021 | 3217 | 0.260 |
Why?
|
Financing, Government | 1 | 2009 | 469 | 0.260 |
Why?
|
Heart Diseases | 2 | 2015 | 2789 | 0.260 |
Why?
|
Polysaccharides | 1 | 2012 | 1058 | 0.260 |
Why?
|
Sulfonamides | 2 | 2015 | 1938 | 0.260 |
Why?
|
Biomedical Research | 2 | 2020 | 3308 | 0.260 |
Why?
|
Multivariate Analysis | 7 | 2016 | 12243 | 0.260 |
Why?
|
Social Support | 4 | 2022 | 2118 | 0.260 |
Why?
|
Risk Assessment | 17 | 2018 | 23327 | 0.260 |
Why?
|
Health Resources | 1 | 2011 | 912 | 0.250 |
Why?
|
Pericardial Effusion | 1 | 2007 | 247 | 0.250 |
Why?
|
Financial Support | 3 | 2020 | 115 | 0.250 |
Why?
|
Simvastatin | 4 | 2015 | 360 | 0.250 |
Why?
|
Hemorrhage | 8 | 2020 | 3458 | 0.250 |
Why?
|
Therapeutic Equivalency | 3 | 2015 | 141 | 0.250 |
Why?
|
Thiazolidinediones | 3 | 2014 | 475 | 0.250 |
Why?
|
Angina, Unstable | 2 | 2009 | 926 | 0.250 |
Why?
|
Patient Readmission | 1 | 2018 | 3117 | 0.240 |
Why?
|
Phlebotomy | 1 | 2005 | 141 | 0.240 |
Why?
|
Pain | 2 | 2017 | 4987 | 0.240 |
Why?
|
Efficiency, Organizational | 1 | 2009 | 695 | 0.240 |
Why?
|
Brain Ischemia | 3 | 2018 | 3264 | 0.240 |
Why?
|
Depressive Disorder | 1 | 2017 | 3744 | 0.240 |
Why?
|
Multiple Sclerosis | 1 | 2019 | 3079 | 0.240 |
Why?
|
Health Care Reform | 4 | 2016 | 1261 | 0.240 |
Why?
|
Drug Administration Schedule | 6 | 2018 | 4931 | 0.230 |
Why?
|
Epilepsy | 2 | 2016 | 3284 | 0.230 |
Why?
|
Seizures | 1 | 2016 | 2850 | 0.230 |
Why?
|
Reimbursement, Incentive | 1 | 2009 | 540 | 0.230 |
Why?
|
Cross Infection | 1 | 2013 | 1416 | 0.230 |
Why?
|
Surgical Wound Infection | 1 | 2013 | 1539 | 0.230 |
Why?
|
Limb Salvage | 2 | 2023 | 433 | 0.230 |
Why?
|
Sulfonylurea Compounds | 3 | 2014 | 205 | 0.230 |
Why?
|
Psychotropic Drugs | 1 | 2009 | 893 | 0.220 |
Why?
|
Adolescent | 17 | 2019 | 85729 | 0.220 |
Why?
|
Qualitative Research | 2 | 2022 | 2682 | 0.220 |
Why?
|
National Health Programs | 2 | 1997 | 445 | 0.220 |
Why?
|
Hip Fractures | 2 | 2008 | 955 | 0.220 |
Why?
|
Nursing Homes | 1 | 2010 | 1036 | 0.220 |
Why?
|
Patient Protection and Affordable Care Act | 3 | 2016 | 1209 | 0.220 |
Why?
|
Meta-Analysis as Topic | 2 | 2006 | 1340 | 0.220 |
Why?
|
Physician-Patient Relations | 4 | 2016 | 3229 | 0.220 |
Why?
|
Developing Countries | 2 | 2014 | 2815 | 0.210 |
Why?
|
Acute Coronary Syndrome | 2 | 2013 | 2337 | 0.210 |
Why?
|
Resuscitation Orders | 2 | 2003 | 269 | 0.210 |
Why?
|
Internet | 5 | 2016 | 3058 | 0.210 |
Why?
|
Arrhythmias, Cardiac | 2 | 2009 | 2267 | 0.210 |
Why?
|
Radius Fractures | 1 | 2008 | 501 | 0.210 |
Why?
|
Delivery of Health Care | 3 | 2022 | 5319 | 0.210 |
Why?
|
Absorptiometry, Photon | 1 | 2008 | 1725 | 0.210 |
Why?
|
Gout | 2 | 2021 | 571 | 0.200 |
Why?
|
Internship and Residency | 1 | 2022 | 5787 | 0.200 |
Why?
|
Hospital Mortality | 1 | 2015 | 5316 | 0.200 |
Why?
|
Heart Rate | 2 | 2010 | 4091 | 0.200 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 4 | 2015 | 2281 | 0.200 |
Why?
|
Cholesterol, LDL | 1 | 2011 | 2354 | 0.200 |
Why?
|
Cross-Cultural Comparison | 1 | 2005 | 651 | 0.200 |
Why?
|
Proportional Hazards Models | 5 | 2015 | 12354 | 0.190 |
Why?
|
Choice Behavior | 2 | 2019 | 802 | 0.190 |
Why?
|
Surgical Procedures, Operative | 4 | 2018 | 1877 | 0.190 |
Why?
|
Continuity of Patient Care | 1 | 2008 | 1049 | 0.190 |
Why?
|
Program Evaluation | 5 | 2021 | 2483 | 0.190 |
Why?
|
Vascular Surgical Procedures | 2 | 2022 | 1476 | 0.190 |
Why?
|
Incidence | 9 | 2018 | 20948 | 0.190 |
Why?
|
Clinical Competence | 3 | 2006 | 4687 | 0.180 |
Why?
|
Fees, Pharmaceutical | 2 | 2014 | 64 | 0.180 |
Why?
|
Health Policy | 6 | 2020 | 2662 | 0.180 |
Why?
|
Interferon-gamma | 1 | 2009 | 3205 | 0.180 |
Why?
|
Forecasting | 3 | 2018 | 2950 | 0.180 |
Why?
|
Sex Factors | 5 | 2015 | 10394 | 0.180 |
Why?
|
Acute Kidney Injury | 1 | 2012 | 1968 | 0.180 |
Why?
|
Needs Assessment | 2 | 2017 | 1146 | 0.180 |
Why?
|
Venous Thromboembolism | 1 | 2012 | 1670 | 0.180 |
Why?
|
Hypercholesterolemia | 1 | 2006 | 1151 | 0.180 |
Why?
|
Alopecia | 1 | 2023 | 382 | 0.170 |
Why?
|
Patient Satisfaction | 3 | 2021 | 3391 | 0.170 |
Why?
|
Caregivers | 1 | 2011 | 2098 | 0.170 |
Why?
|
Medical Oncology | 1 | 2011 | 2267 | 0.170 |
Why?
|
Heart Murmurs | 1 | 1999 | 94 | 0.170 |
Why?
|
Peripheral Arterial Disease | 2 | 2023 | 1188 | 0.170 |
Why?
|
Dipeptidyl-Peptidase IV Inhibitors | 2 | 2014 | 293 | 0.170 |
Why?
|
Beneficence | 2 | 2009 | 53 | 0.170 |
Why?
|
Attitude of Health Personnel | 3 | 2015 | 3839 | 0.170 |
Why?
|
Sensitivity and Specificity | 5 | 2020 | 14714 | 0.170 |
Why?
|
Toluidines | 1 | 2019 | 19 | 0.170 |
Why?
|
Crotonates | 1 | 2019 | 19 | 0.170 |
Why?
|
Clinical Trials as Topic | 4 | 2011 | 7908 | 0.170 |
Why?
|
Behavior Control | 1 | 2019 | 45 | 0.170 |
Why?
|
Primary Prevention | 1 | 2006 | 1167 | 0.170 |
Why?
|
C-Reactive Protein | 1 | 2011 | 3778 | 0.170 |
Why?
|
Herpes Zoster Vaccine | 1 | 2019 | 47 | 0.170 |
Why?
|
Case-Control Studies | 5 | 2016 | 21733 | 0.170 |
Why?
|
Risk | 4 | 2018 | 9677 | 0.170 |
Why?
|
Behavioral Sciences | 1 | 2018 | 31 | 0.170 |
Why?
|
Hydroxybutyrates | 1 | 2019 | 82 | 0.160 |
Why?
|
Pyrimidines | 1 | 2011 | 2945 | 0.160 |
Why?
|
Posture | 1 | 2023 | 957 | 0.160 |
Why?
|
Endovascular Procedures | 3 | 2023 | 1980 | 0.160 |
Why?
|
Combined Modality Therapy | 3 | 2022 | 8637 | 0.160 |
Why?
|
Diagnostic Tests, Routine | 1 | 2004 | 782 | 0.160 |
Why?
|
Comorbidity | 5 | 2020 | 10380 | 0.160 |
Why?
|
Education, Medical | 1 | 2010 | 1722 | 0.160 |
Why?
|
Patient Selection | 3 | 2019 | 4210 | 0.160 |
Why?
|
Smoking | 4 | 2016 | 8984 | 0.150 |
Why?
|
Education, Distance | 1 | 2021 | 251 | 0.150 |
Why?
|
Recurrence | 5 | 2019 | 8337 | 0.150 |
Why?
|
Disease Progression | 5 | 2020 | 13273 | 0.150 |
Why?
|
Canada | 5 | 2021 | 2064 | 0.150 |
Why?
|
Teaching Rounds | 1 | 2021 | 253 | 0.150 |
Why?
|
Remote Consultation | 1 | 2020 | 239 | 0.150 |
Why?
|
Anemia | 2 | 2005 | 1502 | 0.150 |
Why?
|
Models, Econometric | 2 | 2009 | 218 | 0.150 |
Why?
|
Prospective Studies | 10 | 2021 | 53250 | 0.150 |
Why?
|
Informed Consent | 3 | 2013 | 995 | 0.150 |
Why?
|
Adenosine Diphosphate | 1 | 2018 | 425 | 0.150 |
Why?
|
Coronary Angiography | 1 | 2009 | 4576 | 0.150 |
Why?
|
Decision Making, Organizational | 1 | 1997 | 139 | 0.150 |
Why?
|
Minnesota | 2 | 2009 | 344 | 0.140 |
Why?
|
Proton Pump Inhibitors | 2 | 2013 | 526 | 0.140 |
Why?
|
Women's Health | 1 | 2006 | 2033 | 0.140 |
Why?
|
Physical Examination | 4 | 2009 | 1235 | 0.140 |
Why?
|
Sulfasalazine | 1 | 2016 | 79 | 0.140 |
Why?
|
Physician Incentive Plans | 1 | 2017 | 161 | 0.140 |
Why?
|
Ethics Committees, Research | 1 | 2017 | 194 | 0.140 |
Why?
|
Decision Support Techniques | 2 | 2017 | 1956 | 0.130 |
Why?
|
Immunization Programs | 1 | 2018 | 260 | 0.130 |
Why?
|
Community Health Planning | 1 | 2016 | 165 | 0.130 |
Why?
|
Organizational Innovation | 2 | 2016 | 559 | 0.130 |
Why?
|
Names | 1 | 2015 | 52 | 0.130 |
Why?
|
Pneumococcal Vaccines | 1 | 2019 | 391 | 0.130 |
Why?
|
Pyridines | 2 | 2017 | 2827 | 0.130 |
Why?
|
Interprofessional Relations | 1 | 2002 | 1009 | 0.130 |
Why?
|
Spine | 1 | 2022 | 1144 | 0.130 |
Why?
|
Anti-Bacterial Agents | 2 | 2013 | 7172 | 0.130 |
Why?
|
Quality of Life | 4 | 2023 | 12788 | 0.130 |
Why?
|
Morbidity | 2 | 2013 | 1768 | 0.130 |
Why?
|
Cross-Sectional Studies | 10 | 2024 | 25032 | 0.130 |
Why?
|
Privacy | 1 | 2017 | 238 | 0.130 |
Why?
|
Minority Groups | 1 | 2023 | 1222 | 0.130 |
Why?
|
Organizational Policy | 2 | 1994 | 428 | 0.130 |
Why?
|
Lisinopril | 1 | 2015 | 54 | 0.130 |
Why?
|
Public Opinion | 1 | 2019 | 477 | 0.130 |
Why?
|
Xanthine Oxidase | 1 | 2015 | 64 | 0.130 |
Why?
|
Delayed-Action Preparations | 1 | 2018 | 967 | 0.130 |
Why?
|
Ketorolac | 1 | 2015 | 79 | 0.130 |
Why?
|
Vaccines | 1 | 2023 | 823 | 0.130 |
Why?
|
Aortic Valve Insufficiency | 1 | 1999 | 579 | 0.130 |
Why?
|
Models, Theoretical | 3 | 2016 | 3587 | 0.120 |
Why?
|
Cardiopulmonary Resuscitation | 1 | 2003 | 980 | 0.120 |
Why?
|
Counseling | 1 | 2022 | 1523 | 0.120 |
Why?
|
Minority Health | 1 | 2015 | 87 | 0.120 |
Why?
|
Residence Characteristics | 2 | 2015 | 2050 | 0.120 |
Why?
|
Uridine Monophosphate | 1 | 2015 | 70 | 0.120 |
Why?
|
Insulin, Long-Acting | 1 | 2014 | 57 | 0.120 |
Why?
|
Adrenal Cortex Hormones | 1 | 2023 | 1854 | 0.120 |
Why?
|
Disease Management | 3 | 2015 | 2459 | 0.120 |
Why?
|
Authorship | 2 | 2011 | 271 | 0.120 |
Why?
|
Attitude to Health | 4 | 2014 | 2052 | 0.120 |
Why?
|
Ischemia | 3 | 2023 | 1907 | 0.120 |
Why?
|
Health Care Rationing | 1 | 1997 | 437 | 0.120 |
Why?
|
Genotype | 3 | 2015 | 12944 | 0.120 |
Why?
|
Reproducibility of Results | 5 | 2015 | 19894 | 0.120 |
Why?
|
Antineoplastic Agents | 2 | 2017 | 13691 | 0.120 |
Why?
|
Electronic Mail | 1 | 2016 | 213 | 0.120 |
Why?
|
Oseltamivir | 1 | 2014 | 75 | 0.120 |
Why?
|
Poverty Areas | 1 | 2015 | 275 | 0.120 |
Why?
|
Government Regulation | 3 | 2009 | 522 | 0.120 |
Why?
|
Angiotensin II Type 1 Receptor Blockers | 2 | 2014 | 452 | 0.120 |
Why?
|
Fluorenes | 1 | 2015 | 160 | 0.120 |
Why?
|
Biotransformation | 1 | 2013 | 168 | 0.120 |
Why?
|
Patient Care Team | 2 | 2023 | 2528 | 0.120 |
Why?
|
Pulse | 2 | 2007 | 228 | 0.120 |
Why?
|
Nitriles | 1 | 2019 | 953 | 0.120 |
Why?
|
Mesalamine | 1 | 2014 | 136 | 0.110 |
Why?
|
Carbamates | 1 | 2015 | 196 | 0.110 |
Why?
|
Gout Suppressants | 1 | 2015 | 165 | 0.110 |
Why?
|
Dosage Forms | 1 | 2013 | 56 | 0.110 |
Why?
|
Information Systems | 1 | 2015 | 410 | 0.110 |
Why?
|
Valine | 1 | 2015 | 413 | 0.110 |
Why?
|
Professional-Patient Relations | 2 | 2016 | 737 | 0.110 |
Why?
|
Heterocyclic Compounds, 3-Ring | 1 | 2015 | 215 | 0.110 |
Why?
|
Information Dissemination | 2 | 2012 | 1099 | 0.110 |
Why?
|
Blue Cross Blue Shield Insurance Plans | 1 | 2013 | 94 | 0.110 |
Why?
|
Reimbursement Mechanisms | 2 | 2010 | 670 | 0.110 |
Why?
|
Ribavirin | 1 | 2015 | 394 | 0.110 |
Why?
|
Life Support Care | 1 | 1994 | 228 | 0.110 |
Why?
|
Outpatients | 2 | 2017 | 1488 | 0.110 |
Why?
|
Pyrrolidines | 1 | 2015 | 341 | 0.110 |
Why?
|
Color | 2 | 2013 | 304 | 0.110 |
Why?
|
Intestinal Diseases, Parasitic | 1 | 2013 | 66 | 0.110 |
Why?
|
Family Practice | 1 | 1996 | 516 | 0.110 |
Why?
|
Cryptosporidium parvum | 1 | 2013 | 43 | 0.110 |
Why?
|
Advance Directives | 1 | 1994 | 246 | 0.110 |
Why?
|
Anti-Ulcer Agents | 1 | 2013 | 119 | 0.110 |
Why?
|
Osteoarthritis, Hip | 1 | 2017 | 412 | 0.110 |
Why?
|
Angioplasty, Balloon, Coronary | 2 | 2011 | 1874 | 0.110 |
Why?
|
Salaries and Fringe Benefits | 1 | 2015 | 263 | 0.110 |
Why?
|
Cryptosporidiosis | 1 | 2013 | 60 | 0.110 |
Why?
|
Hydroxychloroquine | 1 | 2016 | 412 | 0.110 |
Why?
|
Histamine H2 Antagonists | 1 | 2013 | 165 | 0.110 |
Why?
|
Health Services Misuse | 1 | 2014 | 243 | 0.100 |
Why?
|
alpha-Glucosidases | 1 | 2012 | 44 | 0.100 |
Why?
|
Self Care | 1 | 2017 | 786 | 0.100 |
Why?
|
Thiazoles | 2 | 2017 | 1482 | 0.100 |
Why?
|
Public Policy | 2 | 2008 | 572 | 0.100 |
Why?
|
Case Management | 1 | 2014 | 286 | 0.100 |
Why?
|
Influenza Vaccines | 1 | 2019 | 738 | 0.100 |
Why?
|
Vitamin K | 1 | 2014 | 295 | 0.100 |
Why?
|
Back Pain | 1 | 2016 | 544 | 0.100 |
Why?
|
Benzodiazepines | 2 | 2016 | 1101 | 0.100 |
Why?
|
Zoonoses | 1 | 2013 | 183 | 0.100 |
Why?
|
Heptanoic Acids | 3 | 2010 | 343 | 0.100 |
Why?
|
Health Services | 2 | 2013 | 758 | 0.100 |
Why?
|
Patient Care Planning | 1 | 2017 | 915 | 0.100 |
Why?
|
Tachycardia, Paroxysmal | 1 | 2011 | 31 | 0.100 |
Why?
|
Access to Information | 1 | 2014 | 320 | 0.100 |
Why?
|
Adenosine | 1 | 2016 | 825 | 0.100 |
Why?
|
Atrioventricular Node | 1 | 2011 | 182 | 0.100 |
Why?
|
Azetidines | 1 | 2012 | 142 | 0.100 |
Why?
|
Developed Countries | 1 | 2014 | 437 | 0.100 |
Why?
|
Cross-Over Studies | 1 | 2016 | 2029 | 0.100 |
Why?
|
Adaptation, Psychological | 1 | 2021 | 2575 | 0.090 |
Why?
|
Electrocardiography | 3 | 2010 | 6441 | 0.090 |
Why?
|
Extremities | 1 | 2016 | 867 | 0.090 |
Why?
|
Chi-Square Distribution | 2 | 2007 | 3503 | 0.090 |
Why?
|
Interferon-alpha | 1 | 2015 | 895 | 0.090 |
Why?
|
Skilled Nursing Facilities | 1 | 1994 | 372 | 0.090 |
Why?
|
Clinical Pharmacy Information Systems | 1 | 2010 | 103 | 0.090 |
Why?
|
Poverty | 2 | 2015 | 2660 | 0.090 |
Why?
|
Age Distribution | 1 | 2016 | 2899 | 0.090 |
Why?
|
Communications Media | 1 | 2010 | 43 | 0.090 |
Why?
|
Anti-Obesity Agents | 1 | 2013 | 217 | 0.090 |
Why?
|
Health Services Research | 2 | 2014 | 1836 | 0.090 |
Why?
|
Preoperative Period | 1 | 2012 | 550 | 0.090 |
Why?
|
Self Medication | 1 | 2011 | 117 | 0.090 |
Why?
|
North America | 1 | 2014 | 1249 | 0.090 |
Why?
|
Withholding Treatment | 1 | 1994 | 599 | 0.090 |
Why?
|
Computer Simulation | 3 | 2019 | 6188 | 0.090 |
Why?
|
Retreatment | 1 | 2011 | 609 | 0.090 |
Why?
|
Influenza A Virus, H1N1 Subtype | 1 | 2014 | 459 | 0.090 |
Why?
|
Clinical Audit | 1 | 2009 | 31 | 0.090 |
Why?
|
Organizational Case Studies | 1 | 2010 | 299 | 0.090 |
Why?
|
Journal Impact Factor | 1 | 2011 | 155 | 0.090 |
Why?
|
Breast Neoplasms | 2 | 2017 | 20827 | 0.090 |
Why?
|
Drug Interactions | 4 | 2017 | 1460 | 0.090 |
Why?
|
Respiratory Tract Diseases | 1 | 2015 | 722 | 0.090 |
Why?
|
Dermatology | 1 | 2019 | 872 | 0.090 |
Why?
|
Methotrexate | 1 | 2016 | 1726 | 0.090 |
Why?
|
Social Class | 1 | 2018 | 1997 | 0.090 |
Why?
|
Drug Combinations | 1 | 2015 | 1958 | 0.090 |
Why?
|
Program Development | 1 | 2016 | 1314 | 0.090 |
Why?
|
Drug Therapy | 1 | 2012 | 496 | 0.090 |
Why?
|
Mental Disorders | 1 | 2009 | 6593 | 0.080 |
Why?
|
Receptors, Estrogen | 1 | 2017 | 2190 | 0.080 |
Why?
|
Gastrointestinal Hemorrhage | 1 | 2016 | 1131 | 0.080 |
Why?
|
Sequence Deletion | 1 | 2013 | 1524 | 0.080 |
Why?
|
Insurance Benefits | 1 | 2010 | 183 | 0.080 |
Why?
|
Embolism | 1 | 2012 | 407 | 0.080 |
Why?
|
Hydrochlorothiazide | 1 | 2009 | 98 | 0.080 |
Why?
|
Glomerular Filtration Rate | 1 | 2016 | 2167 | 0.080 |
Why?
|
Diagnostic Techniques, Cardiovascular | 1 | 2009 | 153 | 0.080 |
Why?
|
Bayes Theorem | 2 | 2015 | 2307 | 0.080 |
Why?
|
Emergency Medical Services | 1 | 2020 | 1917 | 0.080 |
Why?
|
Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2009 | 109 | 0.080 |
Why?
|
Electrophysiologic Techniques, Cardiac | 1 | 2011 | 493 | 0.080 |
Why?
|
Mixed Function Oxygenases | 1 | 2009 | 271 | 0.080 |
Why?
|
Quality Control | 1 | 2011 | 841 | 0.080 |
Why?
|
Drug Packaging | 1 | 2007 | 39 | 0.080 |
Why?
|
Pandemics | 2 | 2021 | 8385 | 0.080 |
Why?
|
Wounds and Injuries | 1 | 2020 | 2401 | 0.080 |
Why?
|
Anticholesteremic Agents | 2 | 2012 | 979 | 0.080 |
Why?
|
Severity of Illness Index | 2 | 2016 | 15526 | 0.080 |
Why?
|
Hepacivirus | 1 | 2015 | 1378 | 0.080 |
Why?
|
India | 1 | 2014 | 2200 | 0.070 |
Why?
|
State Government | 1 | 2010 | 372 | 0.070 |
Why?
|
Health Care Surveys | 2 | 2019 | 2453 | 0.070 |
Why?
|
Altruism | 1 | 2009 | 204 | 0.070 |
Why?
|
Pyrroles | 3 | 2010 | 1147 | 0.070 |
Why?
|
Pericardiocentesis | 1 | 2007 | 74 | 0.070 |
Why?
|
Child, Preschool | 5 | 2016 | 40964 | 0.070 |
Why?
|
Medical Audit | 1 | 2008 | 466 | 0.070 |
Why?
|
Lovastatin | 1 | 2007 | 120 | 0.070 |
Why?
|
Tryptophan | 1 | 2009 | 478 | 0.070 |
Why?
|
Osteoarthritis, Knee | 1 | 2017 | 1222 | 0.070 |
Why?
|
Antirheumatic Agents | 1 | 2016 | 1338 | 0.070 |
Why?
|
Editorial Policies | 1 | 2011 | 451 | 0.070 |
Why?
|
Factor Analysis, Statistical | 1 | 2009 | 975 | 0.070 |
Why?
|
Arthroplasty, Replacement, Hip | 1 | 2017 | 1462 | 0.070 |
Why?
|
Biological Products | 1 | 2015 | 859 | 0.070 |
Why?
|
Quinolines | 1 | 2011 | 732 | 0.070 |
Why?
|
Medical History Taking | 1 | 2009 | 782 | 0.070 |
Why?
|
Arthroplasty, Replacement, Knee | 1 | 2017 | 1458 | 0.070 |
Why?
|
Evaluation Studies as Topic | 1 | 2008 | 1677 | 0.070 |
Why?
|
Family Health | 1 | 2011 | 1280 | 0.070 |
Why?
|
Ontario | 2 | 1997 | 383 | 0.070 |
Why?
|
Eligibility Determination | 1 | 2009 | 404 | 0.070 |
Why?
|
Heart Conduction System | 1 | 2011 | 1047 | 0.060 |
Why?
|
Cerebral Hemorrhage | 1 | 2016 | 2647 | 0.060 |
Why?
|
Pulmonary Veins | 1 | 2011 | 761 | 0.060 |
Why?
|
Early Detection of Cancer | 1 | 2019 | 3089 | 0.060 |
Why?
|
Emergency Service, Hospital | 3 | 2015 | 7658 | 0.060 |
Why?
|
Data Interpretation, Statistical | 3 | 2019 | 2715 | 0.060 |
Why?
|
Pravastatin | 1 | 2007 | 395 | 0.060 |
Why?
|
Longitudinal Studies | 3 | 2017 | 13980 | 0.060 |
Why?
|
Hospitals, Special | 1 | 2005 | 101 | 0.060 |
Why?
|
Calcitonin | 1 | 2006 | 336 | 0.060 |
Why?
|
Physician Self-Referral | 1 | 2004 | 18 | 0.060 |
Why?
|
Economics, Medical | 1 | 2005 | 113 | 0.060 |
Why?
|
Privatization | 1 | 2004 | 41 | 0.060 |
Why?
|
Postmenopause | 1 | 2013 | 2458 | 0.060 |
Why?
|
Safety | 1 | 2009 | 1184 | 0.060 |
Why?
|
Early Diagnosis | 1 | 2009 | 1186 | 0.060 |
Why?
|
Hematocrit | 1 | 2005 | 636 | 0.060 |
Why?
|
Registries | 1 | 2019 | 8090 | 0.060 |
Why?
|
Blood Volume | 1 | 2005 | 565 | 0.060 |
Why?
|
Migraine Disorders | 1 | 2016 | 1620 | 0.060 |
Why?
|
Professional Misconduct | 1 | 2004 | 73 | 0.060 |
Why?
|
Life Style | 1 | 2015 | 3833 | 0.060 |
Why?
|
Comprehension | 1 | 2009 | 610 | 0.060 |
Why?
|
Liability, Legal | 1 | 2005 | 213 | 0.060 |
Why?
|
Exercise | 1 | 2019 | 5611 | 0.060 |
Why?
|
Physician's Role | 1 | 2010 | 942 | 0.060 |
Why?
|
Cholinergic Antagonists | 1 | 2024 | 165 | 0.050 |
Why?
|
Hospitals, Community | 1 | 2005 | 347 | 0.050 |
Why?
|
Drug Discovery | 1 | 2011 | 1058 | 0.050 |
Why?
|
Length of Stay | 3 | 2017 | 6311 | 0.050 |
Why?
|
Surgery, Computer-Assisted | 1 | 2011 | 1017 | 0.050 |
Why?
|
Cluster Analysis | 2 | 2020 | 2712 | 0.050 |
Why?
|
Alleles | 1 | 2013 | 6934 | 0.050 |
Why?
|
Perception | 1 | 2009 | 1198 | 0.050 |
Why?
|
Weight Loss | 1 | 2013 | 2625 | 0.050 |
Why?
|
Health Care Sector | 1 | 2004 | 194 | 0.050 |
Why?
|
Selection Bias | 1 | 2004 | 371 | 0.050 |
Why?
|
Lactones | 2 | 2015 | 329 | 0.050 |
Why?
|
Colitis, Ulcerative | 1 | 2014 | 1911 | 0.050 |
Why?
|
Prognosis | 2 | 2020 | 29052 | 0.050 |
Why?
|
Health Status | 1 | 2015 | 4031 | 0.050 |
Why?
|
Pneumonia | 1 | 2013 | 2133 | 0.050 |
Why?
|
Medical Records Systems, Computerized | 1 | 2008 | 1204 | 0.050 |
Why?
|
Child | 5 | 2016 | 77637 | 0.050 |
Why?
|
Models, Biological | 1 | 2018 | 9582 | 0.050 |
Why?
|
Medicine | 1 | 2010 | 945 | 0.050 |
Why?
|
Cardiology | 1 | 2012 | 1668 | 0.050 |
Why?
|
Habits | 1 | 2021 | 139 | 0.050 |
Why?
|
Hemoglobins | 2 | 2005 | 1531 | 0.050 |
Why?
|
Educational Status | 1 | 2009 | 2540 | 0.050 |
Why?
|
Private Sector | 1 | 2004 | 393 | 0.050 |
Why?
|
Immunity, Innate | 1 | 2013 | 2961 | 0.050 |
Why?
|
Arthritis, Rheumatoid | 1 | 2016 | 3712 | 0.050 |
Why?
|
Epidemiologic Methods | 1 | 2006 | 1364 | 0.050 |
Why?
|
Cognition Disorders | 1 | 2015 | 4041 | 0.050 |
Why?
|
Iron | 1 | 2009 | 1774 | 0.050 |
Why?
|
American Medical Association | 2 | 2005 | 65 | 0.050 |
Why?
|
Infant | 4 | 2014 | 35122 | 0.040 |
Why?
|
Nitric Oxide | 1 | 2009 | 2132 | 0.040 |
Why?
|
Confidence Intervals | 3 | 2013 | 2971 | 0.040 |
Why?
|
Malpractice | 1 | 2005 | 572 | 0.040 |
Why?
|
Heart Auscultation | 1 | 1999 | 37 | 0.040 |
Why?
|
Substance-Related Disorders | 1 | 2016 | 4254 | 0.040 |
Why?
|
Saphenous Vein | 1 | 2022 | 532 | 0.040 |
Why?
|
Iatrogenic Disease | 1 | 2003 | 546 | 0.040 |
Why?
|
Estrogen Replacement Therapy | 1 | 2006 | 1203 | 0.040 |
Why?
|
Thromboembolism | 1 | 2006 | 987 | 0.040 |
Why?
|
Linear Models | 1 | 2009 | 5952 | 0.040 |
Why?
|
Stroke Volume | 2 | 2023 | 5002 | 0.040 |
Why?
|
Cell Survival | 1 | 2009 | 5881 | 0.040 |
Why?
|
Neoplasm Staging | 1 | 2013 | 11036 | 0.040 |
Why?
|
Catheter Ablation | 1 | 2011 | 2758 | 0.040 |
Why?
|
Likelihood Functions | 2 | 2018 | 1004 | 0.040 |
Why?
|
Fumarates | 1 | 2018 | 132 | 0.040 |
Why?
|
Disease-Free Survival | 1 | 2008 | 6895 | 0.040 |
Why?
|
Inpatients | 2 | 2021 | 2515 | 0.040 |
Why?
|
Pregnancy | 2 | 2017 | 29140 | 0.040 |
Why?
|
Pallor | 1 | 1997 | 5 | 0.040 |
Why?
|
Value of Life | 1 | 1997 | 97 | 0.040 |
Why?
|
Delphi Technique | 1 | 2020 | 777 | 0.040 |
Why?
|
Probability | 1 | 2003 | 2505 | 0.040 |
Why?
|
Survival Rate | 1 | 2011 | 12786 | 0.040 |
Why?
|
Fractures, Bone | 1 | 2009 | 1946 | 0.040 |
Why?
|
Mitral Valve Stenosis | 1 | 1999 | 376 | 0.040 |
Why?
|
Diastole | 1 | 1999 | 791 | 0.040 |
Why?
|
Hospitals | 2 | 2011 | 3953 | 0.040 |
Why?
|
Prepaid Health Plans | 1 | 1996 | 10 | 0.030 |
Why?
|
Administrative Personnel | 1 | 1997 | 187 | 0.030 |
Why?
|
Radiography | 1 | 2007 | 7010 | 0.030 |
Why?
|
Taiwan | 1 | 2017 | 497 | 0.030 |
Why?
|
Thrombolytic Therapy | 1 | 2005 | 2162 | 0.030 |
Why?
|
Amides | 1 | 2018 | 459 | 0.030 |
Why?
|
Etodolac | 1 | 2015 | 20 | 0.030 |
Why?
|
Stents | 2 | 2018 | 3280 | 0.030 |
Why?
|
Regression Analysis | 1 | 2005 | 6457 | 0.030 |
Why?
|
Standard of Care | 1 | 2019 | 564 | 0.030 |
Why?
|
Bronchi | 1 | 2019 | 840 | 0.030 |
Why?
|
Respiratory System Agents | 1 | 2014 | 29 | 0.030 |
Why?
|
Ethics, Institutional | 1 | 1994 | 37 | 0.030 |
Why?
|
Lung Neoplasms | 1 | 2019 | 13112 | 0.030 |
Why?
|
England | 1 | 1996 | 522 | 0.030 |
Why?
|
Echocardiography | 1 | 2007 | 5096 | 0.030 |
Why?
|
Cell Line | 1 | 2009 | 15993 | 0.030 |
Why?
|
Antipsychotic Agents | 1 | 2007 | 3057 | 0.030 |
Why?
|
Phentermine | 1 | 2013 | 33 | 0.030 |
Why?
|
Salicylates | 1 | 2014 | 126 | 0.030 |
Why?
|
Medical Record Linkage | 1 | 2015 | 284 | 0.030 |
Why?
|
Treatment Refusal | 1 | 1997 | 421 | 0.030 |
Why?
|
Survival Analysis | 1 | 2006 | 10251 | 0.030 |
Why?
|
Cyclobutanes | 1 | 2013 | 59 | 0.030 |
Why?
|
Peer Group | 1 | 2018 | 635 | 0.030 |
Why?
|
Policy | 1 | 2017 | 508 | 0.030 |
Why?
|
Regional Health Planning | 1 | 1994 | 97 | 0.030 |
Why?
|
Dissent and Disputes | 1 | 1994 | 141 | 0.030 |
Why?
|
Bronchoscopy | 1 | 2019 | 861 | 0.030 |
Why?
|
Mental Competency | 1 | 1994 | 176 | 0.030 |
Why?
|
Group Processes | 1 | 1994 | 226 | 0.030 |
Why?
|
Conjunctiva | 1 | 1997 | 494 | 0.030 |
Why?
|
Appetite Depressants | 1 | 2013 | 110 | 0.030 |
Why?
|
Data Mining | 1 | 2018 | 537 | 0.030 |
Why?
|
Sulfones | 1 | 2015 | 434 | 0.030 |
Why?
|
United States Federal Trade Commission | 1 | 2012 | 10 | 0.030 |
Why?
|
Calcium | 1 | 2006 | 5755 | 0.030 |
Why?
|
Anastomosis, Surgical | 1 | 2016 | 987 | 0.030 |
Why?
|
Heart Arrest | 1 | 2003 | 1470 | 0.030 |
Why?
|
Sex | 1 | 2012 | 57 | 0.030 |
Why?
|
Endpoint Determination | 1 | 2015 | 601 | 0.030 |
Why?
|
Massachusetts | 2 | 2016 | 8660 | 0.030 |
Why?
|
Peptic Ulcer | 1 | 2013 | 223 | 0.030 |
Why?
|
Hyperuricemia | 1 | 2015 | 210 | 0.030 |
Why?
|
Postoperative Period | 1 | 2017 | 1841 | 0.030 |
Why?
|
Lipids | 1 | 2023 | 3307 | 0.030 |
Why?
|
Aging | 1 | 2011 | 8655 | 0.030 |
Why?
|
Friends | 1 | 2012 | 154 | 0.030 |
Why?
|
Consumer Product Safety | 1 | 2012 | 122 | 0.020 |
Why?
|
Obesity | 1 | 2013 | 12744 | 0.020 |
Why?
|
Cerebrovascular Disorders | 1 | 2018 | 1504 | 0.020 |
Why?
|
Consensus | 1 | 2020 | 2954 | 0.020 |
Why?
|
Blogging | 1 | 2010 | 16 | 0.020 |
Why?
|
Life Expectancy | 1 | 1997 | 1184 | 0.020 |
Why?
|
British Columbia | 1 | 2011 | 244 | 0.020 |
Why?
|
Electronic Prescribing | 1 | 2011 | 121 | 0.020 |
Why?
|
Ventricular Function, Left | 1 | 2023 | 3660 | 0.020 |
Why?
|
Controlled Clinical Trials as Topic | 1 | 2011 | 186 | 0.020 |
Why?
|
Obstetrics | 1 | 2017 | 657 | 0.020 |
Why?
|
Area Under Curve | 1 | 2014 | 1654 | 0.020 |
Why?
|
Artificial Intelligence | 1 | 2023 | 2210 | 0.020 |
Why?
|
Truth Disclosure | 1 | 1994 | 436 | 0.020 |
Why?
|
Education, Pharmacy | 1 | 2009 | 35 | 0.020 |
Why?
|
Drug Information Services | 1 | 2009 | 51 | 0.020 |
Why?
|
Infant, Newborn | 3 | 2014 | 25609 | 0.020 |
Why?
|
Medical Informatics Applications | 1 | 2010 | 186 | 0.020 |
Why?
|
Postoperative Care | 1 | 2015 | 1485 | 0.020 |
Why?
|
Directive Counseling | 1 | 2010 | 166 | 0.020 |
Why?
|
Venous Thrombosis | 1 | 2017 | 1240 | 0.020 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2012 | 841 | 0.020 |
Why?
|
Urban Health Services | 1 | 2009 | 179 | 0.020 |
Why?
|
Pilot Projects | 1 | 2021 | 8316 | 0.020 |
Why?
|
Alendronate | 1 | 2009 | 171 | 0.020 |
Why?
|
Dibenzothiazepines | 1 | 2007 | 103 | 0.020 |
Why?
|
Receptor, erbB-2 | 1 | 2017 | 2418 | 0.020 |
Why?
|
Florida | 1 | 2008 | 435 | 0.020 |
Why?
|
Ibuprofen | 1 | 2009 | 236 | 0.020 |
Why?
|
Dyslipidemias | 1 | 2015 | 851 | 0.020 |
Why?
|
Spironolactone | 1 | 2010 | 382 | 0.020 |
Why?
|
Biopsy | 1 | 2019 | 6750 | 0.020 |
Why?
|
Writing | 1 | 2009 | 206 | 0.020 |
Why?
|
Physicians, Family | 1 | 2009 | 345 | 0.020 |
Why?
|
Neoplasms | 1 | 2015 | 21675 | 0.020 |
Why?
|
Stress, Physiological | 1 | 2013 | 1403 | 0.020 |
Why?
|
Diuretics | 1 | 2009 | 591 | 0.020 |
Why?
|
Animals | 3 | 2019 | 168660 | 0.020 |
Why?
|
Professional Competence | 1 | 2009 | 447 | 0.020 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2020 | 3921 | 0.020 |
Why?
|
Risperidone | 1 | 2007 | 383 | 0.020 |
Why?
|
Terminology as Topic | 1 | 2012 | 1546 | 0.020 |
Why?
|
Lobbying | 1 | 2005 | 32 | 0.020 |
Why?
|
Health Services for the Aged | 1 | 2007 | 269 | 0.020 |
Why?
|
Financial Management, Hospital | 1 | 2005 | 74 | 0.020 |
Why?
|
Pulmonary Embolism | 1 | 2017 | 2375 | 0.020 |
Why?
|
Defensive Medicine | 1 | 2005 | 48 | 0.020 |
Why?
|
Cardiac Pacing, Artificial | 1 | 2008 | 844 | 0.020 |
Why?
|
Mortality | 1 | 2016 | 2862 | 0.020 |
Why?
|
Quinolones | 1 | 2007 | 368 | 0.020 |
Why?
|
Facility Regulation and Control | 1 | 2004 | 24 | 0.020 |
Why?
|
Insurance, Liability | 1 | 2005 | 102 | 0.020 |
Why?
|
Clozapine | 1 | 2007 | 498 | 0.020 |
Why?
|
Neuropsychological Tests | 1 | 1997 | 6976 | 0.010 |
Why?
|
Transcription Factors | 1 | 2024 | 12209 | 0.010 |
Why?
|
Ethics, Professional | 1 | 2004 | 102 | 0.010 |
Why?
|
Gene Expression Profiling | 1 | 2019 | 9440 | 0.010 |
Why?
|
Medically Uninsured | 1 | 2008 | 853 | 0.010 |
Why?
|
Opioid-Related Disorders | 1 | 2017 | 2064 | 0.010 |
Why?
|
Smoking Cessation | 1 | 2014 | 2071 | 0.010 |
Why?
|
California | 1 | 2006 | 1402 | 0.010 |
Why?
|
Mice | 1 | 2009 | 81154 | 0.010 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2013 | 10940 | 0.010 |
Why?
|
Emotions | 1 | 2012 | 2656 | 0.010 |
Why?
|
Policy Making | 1 | 2005 | 554 | 0.010 |
Why?
|
Kidney Transplantation | 1 | 1995 | 4251 | 0.010 |
Why?
|
Health Promotion | 1 | 2012 | 2205 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 1 | 2019 | 20121 | 0.010 |
Why?
|
Dementia | 1 | 2007 | 2518 | 0.010 |
Why?
|
Observer Variation | 1 | 1997 | 2592 | 0.010 |
Why?
|
ROC Curve | 1 | 1997 | 3527 | 0.010 |
Why?
|